Il Dong Pharmaceutical Co., Ltd.

Ildong Pharm Co., Ltd.

Idience Co., Ltd.

Biosynergen, Inc.

Dong-Keun Song

Kyung-Sun Kim

Yoon-Suk Lee

Sun-Young Park

Jae-Hoon Kang

Hong-Sub Lee

Jin-Ah Jeong

Jeong-Geun Kim

Chang-Hee Hong

Kyung-Mi An

Sung-Wook Kwon

Joon-Tae Park

Yong-Don Yun

Jeong-Ah Kim

Kyeo-Jin Kim

Ji-Hye Choi

Hey-Min Hwang

Jeong-Guen Kim

Ju-Young Jung

An-Na Moon

Soo-Jin Lee

Jun-Su Ban

Kyu-Sic Jang

Sung-Ku Choi

Sung-Oh Huh

Hong-Won Suh

Yung-Hi Kim

The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Autotaxin inhibitor compounds

The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Isoxazole derivatives as nuclear receptor agonists and uses thereof

Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology.

Prevention and/or treatment of CNS disorders

The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Phthalazinone derivatives and manufacturing process thereof

The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).

Phtalazinone derivatives and manufacturing process thereof

The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingophosphorylcholine) or derivatives thereof to the subject. The agonist ligands for G2A receptor according to the present invention and pharmaceutical- or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.

Therapeutic use of agonist ligands specific to G2A receptor

Growing community of inventors

Gyeonggi-do, South Korea

Dong-Keun Song